Lundbeck’s migraine drug Vyepti has the potential for vital development if given the inexperienced gentle in Asia, says the corporate’s US CEO.
发布者:BY MARIA OUTZE NIELSEN,转转请注明出处:https://robotalks.cn/lundbeck-to-apply-for-asian-approval-of-blockbuster-migraine-drug-in-2025/